GSK Sees New Round Of “Defensive Mergers” Ahead, CEO Says
Executive Summary
GlaxoSmithKline sees another round of defensive mergers coming in the pharmaceutical industry, CEO J.P. Garnier declared during a securities analysts meeting in London Feb. 14
You may also be interested in...
GlaxoSmithKline Selects European Head Witty To Succeed Garnier As CEO
GlaxoSmithKline's incoming CEO Andrew Witty - the current president of European pharmaceuticals -brings to the post experience with cost-effectiveness that could prove an asset as comparative and cost-effectiveness become increasingly important to the U.S pharmaceutical industry
GlaxoSmithKline Selects European Head Witty To Succeed Garnier As CEO
GlaxoSmithKline's incoming CEO Andrew Witty - the current president of European pharmaceuticals -brings to the post experience with cost-effectiveness that could prove an asset as comparative and cost-effectiveness become increasingly important to the U.S pharmaceutical industry
Mergers May Buy Time, But Fundamental Change Is Necessary, GSK’s Garnier
The spate of large scale mergers at the beginning of the decade provided companies with time to deal with patent expirations, but ultimately firms need to fundamentally change their business model, GlaxoSmithKline CEO J.P. Garnier said